

Beaumont

Colleagues,

The current monoclonal antibody being used for treatment of mild COVID-19, bebtelovimab, retains activity against all circulating variants of SARS-CoV2 to date. Unfortunately, our supply from the state of Michigan has been decreasing, as the demand for drug has outpaced the manufacturer's ability to provide it. As a result, we will be decreasing our infusion clinics to two days per week (Wednesday & Friday) at the Beaumont, Troy campus, and the Lenox campus will no longer be offering mAbs.

We continue to recommend Paxlovid (nirmatrelvir/ritonavir) as a first line agent for early COVID-19 to prevent development of severe illness. It is widely available and many of its drug interactions can be managed safely with dose reductions or temporary discontinuations of other medications. Molnupiravir is an additional, though likely less effective, option that can be considered for use. If interested in finding alternative sites that are administering bebtelovimab, you can [search for them here](#).



COVID-19 Therapeutics Locator

The COVID-19 Therapeutics Locator is an interactive map that assists health care providers with identifying licensed and authorized locations where patients can fill prescriptions or receive therapy. The locator displays public locations with available courses of U.S. Government-procured COVID-19 therapeutics. These therapeutics are available under U.S. Food and Drug Administration (FDA ...
[covid-19-therapeutics-locator-dhhs.hub.arcgis.com](https://dhhs.hub.arcgis.com/covid-19-therapeutics-locator)

If our supply situation improves in the future, we will hopefully be able to increase our utilization of bebtelovimab. There's also a possibility that we may run out at some point in the future, and if that's the case, I will let you know. Please feel free to contact me with any questions.

Jeffrey S. Fischgrund, M.D.
Chief, Clinical Care Programs
Beaumont Health
Chairman, Department of Orthopedic Surgery
Beaumont Hospital, Royal Oak
Professor and Chairman, Orthopedic Surgery
Oakland University William Beaumont School of Medicine

This message was sent to all Beaumont physicians, APPs and residents.